1
|
Nolin E, Gans S, Llamas L, Bandyopadhyay S, Brittain SM, Bernasconi-Elias P, Carter KP, Loureiro JJ, Thomas JR, Schirle M, Yang Y, Guo N, Roma G, Schuierer S, Beibel M, Lindeman A, Sigoillot F, Chen A, Xie KX, Ho S, Reece-Hoyes J, Weihofen WA, Tyskiewicz K, Hoepfner D, McDonald RI, Guthrie N, Dogra A, Guo H, Shao J, Ding J, Canham SM, Boynton G, George EL, Kang ZB, Antczak C, Porter JA, Wallace O, Tallarico JA, Palmer AE, Jenkins JL, Jain RK, Bushell SM, Fryer CJ. Discovery of a ZIP7 inhibitor from a Notch pathway screen. Nat Chem Biol 2019; 15:179-188. [PMID: 30643281 DOI: 10.1038/s41589-018-0200-7] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 11/14/2018] [Indexed: 12/15/2022]
Abstract
The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway. A phenotypic screen identified compounds that interfere with trafficking of Notch and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism. Target identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport family member, in governing Notch trafficking and signaling. Generation and sequencing of a compound-resistant cell line identified a V430E mutation in ZIP7 that confers transferable resistance to the compound NVS-ZP7-4. NVS-ZP7-4 altered zinc in the ER, and an analog of the compound photoaffinity labeled ZIP7 in cells, suggesting a direct interaction between the compound and ZIP7. NVS-ZP7-4 is the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.
Collapse
Affiliation(s)
- Erin Nolin
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Sara Gans
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Luis Llamas
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | | | - Kyle P Carter
- Department of Chemistry and Biochemistry and BioFrontiers Institute, University of Colorado, Boulder, CO, USA
| | | | - Jason R Thomas
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Markus Schirle
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Yi Yang
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Ning Guo
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Guglielmo Roma
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Sven Schuierer
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Martin Beibel
- Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Alicia Lindeman
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Amy Chen
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Kevin X Xie
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Samuel Ho
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | | | | | | | | | - Abhishek Dogra
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Haibing Guo
- Novartis Institutes for Biomedical Research, Shanghai, China
| | - Jian Shao
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Jian Ding
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Geoff Boynton
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Zhao B Kang
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | | - Owen Wallace
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | - Amy E Palmer
- Department of Chemistry and Biochemistry and BioFrontiers Institute, University of Colorado, Boulder, CO, USA
| | | | - Rishi K Jain
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Simon M Bushell
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
| | - Christy J Fryer
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
| |
Collapse
|